BioSpace News Archive

In stark contrast to Democrats who seek to push all Americans into socialized medicine, an Executive Order signed on October 3 by President Donald Trump takes bold steps toward increasing the ability of American seniors to choose the medical care and insurance options best for them, instead of being trapped within increasingly insolvent government-run programs.

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 million in proceeds.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the last participant has completed the planned 24 weeks of study treatment in CENTAUR, a clinical trial assessing the safety and efficacy of AMX0035 in people with ALS.

Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery.

Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 126,363 shares of its common stock to ten new employees.

The Georgia Bio Innovation Summit is the southeast’s largest life science conference, showcasing Georgia’s leadership in innovation to improve the health and well-being of people, animals and the environment.

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA® (benralizumab) in a pre-filled, single-use auto-injector (the FASENRA Pen™).

Eon, a healthcare IT company, identifies patients at risk for future disease and longitudinally tracks care, today announced that it has completed its SOC 2 Type II audit.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today a publication from The University of Texas, MD Anderson Cancer Center entitled, “Pan-Cancer Landscape and Functional Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Lung function data from the STRIDE Registry show a trend toward delay of decline of pulmonary function compared with those in CINRG Duchenne Natural History1